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Abstract—The present experiments were designed to test the hypothesis that prostaglandin (PG) E2 causes vasodilatation
through activation of endothelial NO synthase (eNOS). Aortic rings from mice with targeted deletion of eNOS and
E-prostanoid (EP) receptors were used for contraction studies. Blood pressure changes in response to PGE2 were
measured in conscious mice. Single doses of PGE2 caused concentration-dependent relaxations during contractions to
phenylephrine (EC505*108 mol/L). Relaxation after PGE2 was absent in rings without endothelium and in rings from
eNOS/ mice and was abolished by NG-nitro-L-arginine methyl ester and the soluble guanylate cyclase inhibitor
1H1,2,4-oxadiazolo-[4,3-a]quinoxalin-1-one. In PGE2-relaxed aortic rings, the cGMP content increased significantly.
PGE2-induced relaxations were abolished by the EP4 receptor antagonist AE3–208 (108 mol/L) and mimicked by an
EP4 agonist (AE1–329, 107 mol/L) in the presence of endothelium and eNOS only. Relaxations were attenuated
significantly in rings from EP4/ mice but normal in EP2/. Inhibitors of the cAMP-protein kinase A pathway
attenuated, whereas the inhibitor of protein phosphatase 1C, calyculin (108 mol/L), abolished the PGE2-mediated
relaxation. In aortic rings, PGE2 dephosphorylated eNOS at Thr495. Chronically catheterized eNOS/ mice were
hypertensive (1373.6 mm Hg, n13, versus 1013.9 mm Hg, n9) and exhibited a lower sensitivity of blood
pressure reduction in response to PGE2 compared with wild-type mice. There was no difference in the blood pressure
response to nifedipine. These findings show that PGE2 elicits EP4 receptor-mediated, endothelium-dependent
stimulation of eNOS activity by dephosphorylation at Thr495 resulting in guanylyl cyclase–dependent vasorelaxation and
accumulation of cGMP in aortic rings. (Hypertension. 2007;50:525-530.)
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Prostaglandin (PG) E2 is a physiologically important va-sodilator in several vascular beds.1 PGE2 can bind to and
stimulate a family of specific E-prostanoid (EP) receptors
with 4 distinct subtypes, EP1 to EP4. Of those, the EP2 and
EP4 receptors are functionally associated with vasodilata-
tion.1 EP2 receptors are less abundant than EP4 in most
tissues but are involved in the systemic vasodepressor re-
sponse to PGE2 infusion, and targeted deletion of EP2 results
in salt-sensitive hypertension.2,3 PGE2 signaling through the
EP4 receptor contributes to the systemic vasodepressor re-
sponse to PGE2 in mice,4,5 attenuates ischemia-reperfusion
injury in the heart,6 and maintains the patency of the ductus
arteriosus in fetal life.7 Experiments with inhibitors of NO
synthase have provided data to suggest that NO is an
extracellullar mediator for PGE2-mediated vasodilatation in
various vascular beds.8,9 Local infusion of cyclooxygenase
inhibitors or NO synthase inhibitors in the renal medulla
precipitates hypertension, which would be compatible with a
serial coupling between the pathways also at this site.10,11
However, it is not known whether there exists a direct
interplay between PGE2 and NO formation in the vasculature,
as shown previously to be the case for PGD2.12 PGE2 EP2 and
EP4 receptors are coupled to adenylyl cyclase.1 The EP4
receptor also activates a phosphatidylinositol 3-kinase and
protein kinase B/Akt.13 Both the cAMP/protein kinase A
(PKA) and phosphatidylinositol 3-kinase-protein kinase
B/Akt pathways may augment endothelial NO synthase
(eNOS) activity at the posttranslational level. Thus, recipro-
cal phosphorylation at eNOS-Ser1177 and dephosphorylation at
eNOS-Thr495 (human sequences) control enzyme activity.14–16
Whether the phosphorylation state of eNOS in the vasculature
is altered by PGE2 is unknown. The present study was
designed to test the hypothesis that vasodilatation mediated
by PGE2 is caused by EP4 receptor-mediated phosphoryla-
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tion/dephosphorylation of eNOS with subsequent increased
production of NO. The experiments were performed on rings
of isolated aortae from wild-type mice and mice with targeted
disruption of eNOS and EP receptors. In addition, PGE2 was
infused to conscious unstressed wild-type mice and eNOS/
mice with chronic indwelling catheters to study, at the
systemic level, the dependency of PGE2-mediated blood
pressure changes on eNOS.
Materials and Methods
Isometric Force Measurements in Aorta Rings
Please see the online data supplement available at http://hyper.
ahajournals.org for details on mouse strains. Two rings were pre-
pared per mouse. Four rings (3-mm long) per experiment were
suspended in a Halpern-Mulvany myograph (model 610 mol/L,
Danish Myo Technology A/S) using 200-m pins for recording of
isometric force (PowerLab, ADI Instruments). Rings incubated at
37°C in physiological salt solution equilibrated with 5% CO2 in air
at a pH of 7.4. The rings were normalized at resting tension of 23
mN and allowed to equilibrate for 15 minutes. Please see the data
supplement for details, drugs, and reagents.
Measurements of eNOS Phosphorylation and
cGMP Content
Aortic rings were mounted as described and contracted with phen-
ylephrine (3107 mol/L). PGE2 (107 mol/L) or vehicle was added,
and preparations that relaxed 50% to PGE2 and their controls were
frozen rapidly in liquid nitrogen. Five rings were pooled per
condition. The tissue was homogenized and divided in 2 fractions, 1
for cyclic nucleotide measurement (enzyme immunoassay kits
5810213 and 581001, Cayman Chemical) and 1 for Western blotting
(anti-phospho-eNOS-Thr495 1:2000, Upstate; anti-phospho-Ser1177
1:200, Cell Signaling; and anti- actin 1:1000, Abcam). Please see
the data supplement for details on Western blotting and PCR.
Blood Pressure Measurement
Catheters were placed in the femoral artery and vein for measure-
ment of arterial blood pressure and intravenous infusions, respec-
tively. The catheters were produced as described by Mattson.17 Mice
recovered for 4 days before the experiments were performed. On the
day of the experiment, the artery line was connected to a pressure
transducer (Fo¨hr Medical Instruments GMBH) connected to an
amplifier. The measured arterial blood pressure was converted into a
digital signal by an analog to digital converter (National Instruments,
USB 6008) and read by a computer using Laboratory View (National
Instruments) software. Data were collected at 200 Hz. Systolic,
diastolic, and mean blood pressure and heart rate (HR) were
determined. For detailed protocols, please see the data supplement.
Data Analysis and Statistics
Constriction was expressed either relative to the maximal constric-
tion of the respective substance set to be 100% or relative to
phenylephrine-induced constriction. Relaxation was expressed as
percentage of phenylephrine-induced tone. Data are shown as
meanSEM. For comparison of single and group mean values,
1-way and 2-way ANOVA followed by Bonferroni’s multiple
comparison test were performed, respectively, using GraphPad Prism
software (GraphPad Prism). One sample t test was used for compar-
ing a single mean with a hypothetical value. Values of P0.05 were
considered to indicate statistically significant differences.
Results
Concentration-Response to PGE2 and Roles of
Endothelium and NO Synthase
Phenylephrine caused concentration-dependent, sustained
contractions of mouse aortic rings with a mean –log EC50 of
7.450.19 (n5; data not shown). Acetylcholine (106
mol/L) caused relaxation of preconstricted rings (78.53.1%;
n5; data not shown). Phenylephrine at EC80 (3107 mol/L)
was used in subsequent experiments to constrict the rings.
Addition of PGE2 as a single bolus to constricted rings caused
a rapid and transient relaxation that was present over the full
concentration range tested (105 mol/L; Figure 1A). At 107
mol/L, PGE2 caused a relaxation of 45.56.3% (n6), and
this concentration was used in subsequent experiments to
identify the receptor(s) and cellular transduction pathway
involved. Maximal relaxation (697.5%) was observed at
106 mol/L of PGE2.
Figure 1. A, Concentration-response curve to PGE2 on phenyl-
ephrine-constricted mouse aortic rings. At 109 mol/L there was
significant relaxation (P0.01; 1 sample t test; n6). B, Bar
graphs illustrate average PGE2-induced (107 mol/L) relaxations
of aortic rings from wild-type control mice (WT; n7); in
denuded rings (without endothelium; n6); in the presence of
the eNOS inhibitor L-NAME (n11); in rings from eNOS/ mice
(n6); and in the presence of soluble guanylase cyclase inhibi-
tor 1H1,2,4-oxadiazolo-[4,3-a]quinoxalin-1-one (n6). *Statistically
significant difference between the respective series and WT
(P0.001; ANOVA with posthoc unpaired t test with Bonferroni
correction). C, cGMP concentration in pooled mouse aortic
rings exposed to PGE2 and vehicle. *P0.001, unpaired t test;
n5 separate preparations at each condition.
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When PGE2 was added cumulatively with no washing steps
between each concentration (1011 to 105 mol/L, 10 minutes
at each concentration), PGE2 had no dilatory effect but
elicited contraction at high concentrations (in quiescent rings:
pEC50 4.890.06, n5; and in preconstricted rings: pEC50
5.890.06, n4; data not shown). As observed previously,18
PGE2-induced contraction was inhibited by thromboxane
receptor antagonists (S18886; –log IC507.910.10, n5;
and SQ29548: –log IC507.470.02, n4; data not shown).
PGE2-induced contractions were absent in rings from mice
with targeted disruption of the thromboxane receptor, al-
though they contracted to phenylephrine (data not shown;
n5). In subsequent experiments, a TP antagonist (S18886)
was present (107 mol/L), and only bolus applications of
prostanoids and analogs were given.
Removal of the endothelium abolished relaxations to ace-
tylcholine (106 mol/L, data not shown) and to PGE2 (Figure
1B). Subsequent exposure to the NO donor sodium nitroprus-
side (SNP) (106 mol/L) relaxed the same rings to the level of
basal tone (data not shown; n6). Incubation of endotheli-
um-intact rings with NG-nitro-L-arginine methyl ester (L-
NAME; 104 mol/L, 30 minutes) eliminated PGE2-induced
relaxations (Figure 1B; n11). In rings prepared from
eNOS/ mice, acetylcholine (data not shown) and PGE2 did
not alter vascular tone (Figure 1B; n6). The same rings
displayed complete relaxation after application of SNP (106
mol/L; data not shown). Inhibition of soluble guanylate
cyclase with 1H1,2,4-oxadiazolo-[4,3-a]quinoxalin-1-one (106
mol/L) prevented PGE2-mediated relaxation in a reversible
fashion (Figure 1B; n6). In PGE2-dilated rings (483%;
n40), the cGMP content increased significantly compared
with control rings (Figure 1C; n5).
EP Receptors Involved in the Relaxation to PGE2
An EP4 receptor-selective antagonist (AE3–208 108 mol/L;
15 minutes) abolished the relaxation to PGE2 (Figure 2A;
n8). In rings from EP4/ mice, the relaxation to PGE2 was
attenuated significantly but not abolished (Figure 2A; n4).
The EP4 receptor-specific agonist AE1–329 (107 mol/L)
produced significant relaxation in rings from wild-type mice
(Figure 2A, right; n11) but had no effect on vascular tone in
rings from eNOS/ mice (n4) and in rings from wild-type
mice treated with L-NAME (104 mol/L; 30 minutes; n8;
Figure 2A, right). In rings prepared from EP2 receptor-
deficient mice (EP2/), PGE2 (107 mol/L) caused relax-
ations that were indistinguishable from those observed in
rings from wild-type mice (Figure 2B; n4). The EP2
receptor-specific agonist butaprost (106 mol/L) marginally
affected tone in preconstricted rings (Figure 2B; 4.81.4%
relaxation; n7). PCR analysis of RNA from whole aorta
showed significant expression of predominantly EP4 recep-
tors (Figure 2C).
Signaling Pathways for PGE2-Induced Activation
of eNOS
The cAMP-dependent protein kinase A inhibitors Rp-8-Br-
cAMPs (104 mol/L; 45 minutes) and KT5720 (106 mol/L;
45 minutes; n7) significantly attenuated the PGE2-induced
relaxation (Figure 3A; n6). The adenylate cyclase inhibitor
SQ22536 (104 mol/L; 45 minutes; n6) yielded similar
results (Figure 3A). Relaxation to acetylcholine was not
affected significantly by blockers of the cAMP-PKA pathway
(data not shown). In PGE2-relaxed rings (50.33%; n25),
cAMP was not significantly elevated compared with control
(38.57 pmol/mg versus 30.19 pmol/mg; n5; P0.1).
Inhibitors of phosphatidylinositol 3-kinase (LY294002: 105
mol/L, n4; and wortmannin: 107 and 106 mol/L, n4
each; data not shown) and mitogen-activated protein kinase
(PD98059; 2105 mol/L; 30 minutes; n3) did not affect
the PGE2-induced relaxation significantly (Figure 3B). Incu-
bation of rings with an inhibitor of protein phosphatase 1C,
calyculin A,19 (108 mol/L; 30 minutes) had no effect on
relaxations to acetylcholine (data not shown) but abolished
those to PGE2 (Figure 3B; n11). In phenylephrine-
contracted mouse aortic rings, Ser1177 phospho-eNOS was
hardly detectable by Western blotting (data not shown),
whereas Thr495-phospho-eNOS was readily detectable (Figure
3C). Exposure of preconstricted aortae rings to PGE2 caused
significant dephosphorylation at Thr495 (Figure 3C; n5),
whereas Ser1177 phospho-eNOS did not change significantly
(data not shown).
Figure 2. A, left, Effect of PGE2 in rings from control mice (wild-type [WT]; n7), in the presence of EP4 receptor antagonist (AE3-208;
n8) and in rings from EP4/ mice (n4). Right, Effect of an EP4-receptor agonist (AE1-329; 107 mol/L) in rings from WT mice
(n11), from eNOS/ mice (n4), and from WT mice in the presence of the NOS inhibitor L-NAME (n8). *P0.001 (ANOVA and
posthoc unpaired t test with Bonferroni correction). #P0.05, 1 sample t test. B, Effect of PGE2 in aortic rings from control mice (WT)
and in rings prepared from EP2/ mice (n4). Effect of the EP2-agonist butaprost (106 mol/L) in constricted rings from WT mice
(n7). *P0.001 (ANOVA and posthoc unpaired t test with Bonferroni correction). #P0.05, 1 sample t test. C, Lanes 1 to 3, PCR
amplification of cDNA from whole aorta for EP receptors and -actin (positive control). Lane 4: negative control, omission of reverse
transcriptase. Lane 5: positive control, mouse kidney cDNA. Lane 6: size marker, X174DNA/HaeIII fragments.
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Arterial Blood Pressure Response to PGE2 in
Wild-Type and eNOS/ Mice
In wild-type mice, the resting mean systolic blood pressure
was 1013.9 mm Hg, and HR was 64023 bpm (n9). In
eNOS/ mice, arterial pressure was elevated significantly
(1373.6 mm Hg; n13; Figure 4A and 1B) and HR was not
different from control (62523 bpm). Injection of a saline
bolus had no effect on arterial blood pressure or HR in either
wild-type or eNOS/ (Figure 4B). Two consecutive applica-
tions of PGE2 (bolus of 50 g/kg; 1-hour interval) led to a
similar decrease in arterial blood pressure during first and
second application in wild-type mice (pressure after PGE2
in mm Hg; 562.5 and 570.9; n4; first and second
application, respectively) and in eNOS/ mice (1009.5 and
994.6; n6; Figure 4B). The maximal response occurred
within the first minutes after the bolus injection. Dose-
response experiments showed that PGE2 had no significant
effect in either strain at 10 g/kg (data not shown). At 25
g/kg, PGE2 caused a significant decrease in arterial blood
pressure in wild-type mice only (Figure 4C; from 1007.0 to
836.7 mm Hg; n5). There was no difference in HR in
response to 25 g/kg of PGE2 in wild-type compared with
eNOS/ mice (11.53.4% versus 6.92.2% increase;
P0.29). A bolus of 50 g/kg of PGE2 decreased blood
pressure significantly in both wild-type and eNOS/ mice
(Figure 4C). The relative blood pressure decrease to 25 g/kg
and 50 g/kg of PGE2 was significantly larger in wild-type
mice compared with eNOS/ mice (Figure 4C). There was
no significant difference in the blood pressure response to
nifedipine, which lowered arterial blood pressure by 374%
and 466% in eNOS/ and wild-type mice (Figure 4C).
There was no significant difference in the time to recovery of
blood pressure: in wild-type mice, 3.21.0 minutes and
eNOS/ mice, 3.41.3 minutes.
Discussion
The present study demonstrates an endothelium- and eNOS-
dependent, EP4 receptor-mediated relaxation of an isolated
vessel preparation by PGE2 that is associated with cGMP
accumulation and dephosphorylation of eNOS at Thr495 (Fig-
Figure 3. A, Effect of PGE2 in phenylephrine-constricted aortae in the presence of vehicle (n7) and inhibitors of the cAMP-PKA path-
way: Rp-8-Br-cAMPs (n6), SQ22536 (n6), and KT5720 (n7). *P0.001 control vs vehicle; 1-way ANOVA and posthoc t test with
Bonferroni correction. B, Effect of PGE2 on force in phenylephrine-constricted vessels in the presence of the phosphatidylinositol
3-kinase inhibitor LY249002 (n4); mitogen-activated protein kinase inhibitor PD98058 (n3); and PP1C inhibitor calyculin A (n11).
*P0.001 vehicle vs control, 1-way ANOVA and posthoc t test with Bonferroni correction. C, Bar graph shows the effect of PGE2 on
phospho-eNOS Thr495 level in pooled aortic rings. Mean optical densitySEM; n5 preparations per condition each consisting of 5
separate rings. *P0.001, 1 sample t test.
Figure 4. Arterial blood pressure responses as measured by indwelling catheters in the femoral artery of conscious wild-type and
eNOS/ mice after administration of PGE2. A, Original traces depict typical responses to the bolus injection of PGE2 in wild-type mice
and eNOS/ mice. Mice with targeted disruption of eNOS exhibited significantly elevated baseline blood pressure. B, Bar graphs
depict mean arterial blood pressure in wild-type mice (WT) and eNOS/ mice. The pressure was determined in both strains at base-
line, after administration of saline bolus, and in response to 2 consecutive administrations of PGE2 (50 g/kg). *Statistically significant
difference between wild-type and eNOS/ mice at P0.05. C, Bar graphs show average, relative decrease in arterial pressure in
response to PGE2 administration (in micrograms per kilogram) in wild-type and eNOS/ mice. Nif indicates nifedipine. *Statistically sig-
nificant difference between wild-type and eNOS/ mice at P0.05 (unpaired Student t test).
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ure 5). The novel finding may provide an explanation for the
rapid effects of cyclooxygenase inhibitors or prostanoids on
NO-dependent physiological responses in certain vascular
beds.8–11 The use of an integrated vascular preparation
showed that, after prolonged exposure to PGE2, the EP4
receptor-mediated relaxation waned, and at high concentra-
tions of PGE2, cross-reactivity with thromboxane receptors
was apparent, as reported also in rat aorta.18 It is well
established that EP4 receptors exhibit ligand-mediated desen-
sitization primarily because of internalization.20,21 When
vessels had not been exposed to PGE2 before, the vessels
responded by relaxation at the full range of concentrations.
Removal of the endothelium, L-NAME treatment, or dele-
tion of eNOS abolished the ability of PGE2 to cause relax-
ation, so we infer that smooth-muscle EP4 or EP2 receptors
are of minor significance for relaxation after PGE2 in the
mouse aorta. The initial sequence of events must depend on
EP4 receptor-mediated activation of eNOS, followed by
NO-mediated stimulation of soluble guanylate cyclase with
accumulation of cGMP in the smooth muscle (Figure 5). The
data indicate that PGE2 activates eNOS through formation of
cAMP by the endothelium; vasorelaxation was inhibited by 3
separate blockers of PKA and adenylate cyclase; calcium-
coupled PGE2 EP1 receptors were not detected in the aorta,
and the response depended on phosphoprotein phosphatase
1C (PP1C), which is activated predominantly by the cAMP
pathway19 (Figure 5). cAMP did not increase significantly in
PGE2-relaxed vascular rings. This finding does not exclude
that PGE2 induces formation of cAMP restricted to the
limited pool of endothelial cells in the preparation. The notion
of cAMP-PKA–dependent activation of eNOS by PP1C-
mediated dephosphorylation at Thr495 is consistent with data
obtained in cultured endothelial cells.14,19 PGE2 phosphory-
lates eNOS at Ser1177 in cultured human endothelial cells at
passage 3 to 6.22 This discrepancy with the present study is
likely because of the very different experimental conditions.
It may also reflect that NO-mediated responses display
segmental heterogeneity; they predominate in conduit vessels
like the aorta, and eNOS is also more strongly expressed in
this segment compared with smaller vessels.23,24
The in vivo experiments demonstrated a fall in arterial
blood pressure in response to PGE2, both in eNOS/ and
wild-type mice. The response to PGE2 was less pronounced in
mice with targeted disruption of eNOS than in wild-type
animals. This differential sensitivity is compatible with a
significant contribution of eNOS to the systemic vasodilator
response to PGE2. However, the effect of PGE2 on blood
pressure also involves mechanisms clearly not dependent on
eNOS. Both peripheral vascular and central nervous mecha-
nisms may be involved.25 In the mouse, EP2 and EP4
receptors contribute to the acute depressor effect of PGE2 on
arterial blood pressure.4,5 Thus, EP2 receptors could be respon-
sible for the residual systemic vasodepressor action of PGE2 in
eNOS/ mice, and EP4 receptors associated with vascular
smooth muscle in the arteriolar segments could also participate.
Vasoconstriction because of cross-activation of thromboxane
receptors by prostanoids and isoprostanes has been observed in
various preparations.18,26 No significant expression of EP recep-
tors associated with constriction (EP1 and EP3) was observed in
mouse aorta in the present and a previous study.27 Moreover, the
dissociation constant values for PGE2 at EP1 and EP3 receptors
are significantly lower than the concentrations of PGE2 required
to mediate constriction in the present study.28 These observa-
tions permit the conclusion that PGE2 is a low-affinity agonist at
the thromboxane receptor in the mouse aorta, as observed
previously in the rat aorta.18
Perspectives
The present data provide evidence for a novel pathway
between PGE2 and eNOS activity initiated by endothelial EP4
receptor occupation and mediated by PP1C-dependent de-
phosphorylation of eNOS. This pathway is relevant not only
for physiological regulation of vascular tone and blood flow
but may also contribute to other vascular processes influ-
enced by eNOS activity, such as platelet aggregation and
smooth muscle cell proliferation.
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